Anke Biotechnology

Anke Biotechnology is a prominent Chinese biopharmaceutical enterprise focused on the research, development, and commercialization of recombinant protein therapeutics and precision medicine. The company's core portfolio includes Ansomone, a leading recombinant human growth hormone, and Anterferon, a recombinant human interferon alpha-2b used for viral and oncological indications. Anke has strategically diversified into monoclonal antibodies, diagnostic reagents, and innovative cell therapies, notably through its CAR-T development programs via its subsidiary PersonGen Anke. Listed on the Shenzhen Stock Exchange since 2009, the company operates extensive GMP-compliant manufacturing facilities and maintains a robust R&D pipeline targeting endocrinology, oncology, and infectious diseases. Its commitment to 'Science for Health' has established it as a key player in the domestic Chinese biotech landscape.